Clarus Therapeutics Expands Executive Team in Preparation for Landmark Launch of JATENZO® (testosterone undecanoate) Capsules CIII
December 11, 2019 14:04 ET
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced the appointment of five senior leaders, each of whom bring valuable industry and category experience to...
Clarus Therapeutics Top-line Results Show Oral Testosterone Replacement Candidate, CLR-610, Meets Phase 3 Study Primary Efficacy Endpoint
September 25, 2012 08:00 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill, Sept. 25, 2012 (GLOBE NEWSWIRE) -- Clarus
Therapeutics, Inc., today reported top-line results from the
Company's ongoing Phase 3 study of
CLR-610, the Company's proprietary oral...
Clarus Therapeutics Strengthens Patent Estate with Issuance of a U.S. Patent Directed to Formulations and Method of Use of Clarus' Oral Testosterone Product
September 19, 2012 08:00 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics,
Inc., today announced that the U.S. Patent and Trademark Office
issued U.S. Patent No. 8,241,664 entitled, "Pharmaceutical...